The histone deacetylase inhibitors industry is witnessing notable expansion due to increasing research activities in oncology and neurology. Pharmaceutical companies are focusing on targeted epigenetic therapies that can improve treatment outcomes for patients with complex disorders. Growing awareness regarding personalized medicine and advancements in drug development technologies are further...